| 证券代码 | TLGT.O |
| 证券名称 | Teligent Inc |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | - |
| 发行方式 | - |
| 首发上市日 | 2015-10-26 |
| 首发价格(元) | - |
| 首发数量(股) | 0 |
| 首发募资额(元) | - |
| 首发主承销商 | - |
| 货币单位 | USD |
| 公司名称 | Teligent, Inc. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 105 Lincoln Ave., Buena, New Jersey, USA |
| 成立日期 | 1977 |
| 董事会主席 | James C. Gale |
| 公司属地 | United States 美国 |
| 公司网址 | www.teligent.com |
| 电话 | +1 (856) 697-1441 |
| 传真 | +1 (856) 697-1442 |
| 公司简介 | Teligent, Inc. develop, manufacture and market pharmaceutical products for use by doctors and patients in the United States and Canada. The Company are a dynamic group of about 150 employees based in New Jersey, Toronto, Montreal and Tallinn, Estonia. Their Product Development and Manufacturing complex is in Buena, New Jersey, approximately 45 minutes from Philadelphia. In 2015 the company acquired Alveda Pharmaceuticals Inc., a Toronto-based pharmaceutical company focused on the Canadian injectable pharmaceutical market. In 2016 the company hired their first European colleagues in Tallinn who support their supply chain and quality operations. Their Quality, Regulatory Affairs and Operations colleagues work closely with their Product Development team to achieve regulatory approval in the countries where the company operate. Their Commercial team sells their portfolio of topical medicines and hospital-based sterile injectable products. The Company are energized about what the company are going to accomplish at Teligent today. The Company believe in taking ownership, driving execution, and making smart, quick decisions. The Company are passionate about their science, and are committed to building a diverse pipeline of topical, injectable, complex and ophthalmic projects. |